Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple oxygen device improve brain death diagnosis?

NCT ID NCT07640009

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial tests whether high-flow humidified oxygen (HHFO) works as well as continuous positive airway pressure (CPAP) for keeping oxygen levels stable during the apnea test, which is used to confirm brain death. The study involves 28 adult intensive care patients who meet all criteria for clinical brain death. Each patient undergoes two apnea tests—one with HHFO and one with CPAP—to compare how well each method maintains oxygenation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High-flow humidified oxygen (HHFO)
What this could lead to
If HHFO works as well as CPAP, it could offer a simpler, safer way to perform apnea tests during brain death diagnosis, potentially improving organ preservation for donation.
What could go wrong
This is a small, early-stage study with only 28 participants, so results may not apply broadly. The trial compares two methods but does not test a new treatment or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult intensive care unit patients * fulfilling all criteria for clinical brain death, for whom confirmation of the absence of spontaneous breathing requires performance of an apnea test * And for whom consent to participate in the study was sought from a trusted person or a family member Exclusion Criteria: * History of chronic obstructive pulmonary disease (COPD) classified as GOLD stage III or IV. * Current extracorporeal life support, including veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO). * PaO₂/FiO₂ ratio ≤ 150 on the most recent arterial blood gas analysis, obtained within 24 hours prior to the screening visit. * Presence of at least one clear or absolute contraindication to the procurement of at least one organ. * Presence of a high cervical spinal cord injury. * Patient in the prone position and/or with a contraindication to placement in the supine position at 30°. * Minor patient. * Protected adult under legal guardianship or curatorship. * Individual under judicial protection (safeguard of justice). * Individuals deprived of liberty. * Individual not covered by a social security or health insurance system. * Pregnant or breastfeeding woman.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Death, brain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Brain Death

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chru de Tours

    Tours, France

  • Chu Angers

    Angers, France

  • Chu Orleans

    Orléans, France

  • Chu de Nantes

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.